This is a Validated Antibody Database (VAD) review about human Skp2, based on 43 published articles (read how Labome selects the articles), using Skp2 antibody in all methods. It is aimed to help Labome visitors find the most suited Skp2 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Skp2 synonym: FBL1; FBXL1; FLB1; p45

Knockout validation
Cell Signaling Technology
domestic rabbit monoclonal (D3G5)
  • western blot knockout validation; human; 1:1000; loading ...; fig 3i
Cell Signaling Technology Skp2 antibody (Cell Signaling, 2652) was used in western blot knockout validation on human samples at 1:1000 (fig 3i). Nat Commun (2018) ncbi
Invitrogen
mouse monoclonal (SKP2-8D9)
  • flow cytometry; mouse; loading ...; fig 5e
Invitrogen Skp2 antibody (eBioscience, 8D9) was used in flow cytometry on mouse samples (fig 5e). J Exp Med (2019) ncbi
mouse monoclonal (SKP2-8D9)
  • flow cytometry; mouse; loading ...; fig 8a
Invitrogen Skp2 antibody (eBioscience, 8D9) was used in flow cytometry on mouse samples (fig 8a). J Exp Med (2019) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; 1:1000; fig 1
In order to investigate activation of APC through Cdh1 binding for Cks1 and Skp2 proteasomal destruction stabilizing p27kip1 for normal endometrial growth by TGF-beta, Invitrogen Skp2 antibody (Invitrogen, 32-3300) was used in western blot on human samples at 1:1000 (fig 1). Cell Cycle (2016) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; 1:1000
In order to study the relationship between SKP2 and MYCN, Invitrogen Skp2 antibody (Invitrogen, 32-3300) was used in western blot on human samples at 1:1000. Cancer Lett (2015) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; 1:2000
In order to study the contribution of the Skp2-mH2A1-CDK8 axis to breast cancer, Invitrogen Skp2 antibody (Invitrogen, 323300) was used in western blot on human samples at 1:2000. Nat Commun (2015) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; mouse
In order to identify the mechanistic link between Cullin neddylation and Myc ubiquitination/degradation, Invitrogen Skp2 antibody (Invitrogen, 32-3300) was used in western blot on mouse samples . Nat Commun (2014) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; 1:500-1:1000
In order to study the effect of imatinib on neuroblastoma cell lines, Invitrogen Skp2 antibody (Life Technologies, 32-3300) was used in western blot on human samples at 1:500-1:1000. Biochem Pharmacol (2014) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human
In order to study the involvement of RASSF1A inactivation in carcinogenesis, Invitrogen Skp2 antibody (Zymed, 32-3300) was used in western blot on human samples . Mol Cell Biol (2014) ncbi
mouse monoclonal (SKP2-8D9)
  • immunohistochemistry - paraffin section; human; 1:100
  • western blot; human; 1:1000; fig 7
In order to investigate the effect of epidermal growth factor on Skp2/Cks1 and p27kip1 in human extrahepatic cholangiocarcinoma cells, Invitrogen Skp2 antibody (Invitrogen, 32-3300) was used in immunohistochemistry - paraffin section on human samples at 1:100 and in western blot on human samples at 1:1000 (fig 7). World J Gastroenterol (2014) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; fig 6
In order to discover a critical role for BRD4 in melanoma tumor maintenance, Invitrogen Skp2 antibody (Invitrogen, 32-3300) was used in western blot on human samples (fig 6). Cancer Res (2013) ncbi
mouse monoclonal (SKP2-8D9)
  • immunoprecipitation; human; fig 2
  • western blot; human; fig 2
In order to elucidate the molecular mechanisms by which pVHL contributes to tumorigenesis, Invitrogen Skp2 antibody (Invitrogen, 32-3300) was used in immunoprecipitation on human samples (fig 2) and in western blot on human samples (fig 2). Oncogene (2011) ncbi
mouse monoclonal (SKP2-8D9)
  • immunocytochemistry; human; fig 1c
  • western blot; human; 1:2000; fig 1a
In order to test if small molecules can restore p27 expression in cancer cells, Invitrogen Skp2 antibody (Zymed Laboratories, 32-3300) was used in immunocytochemistry on human samples (fig 1c) and in western blot on human samples at 1:2000 (fig 1a). BMC Biol (2010) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; fig 8
In order to investigate IL-2-independent mechanisms of naive CD4 positive T cell proliferation, Invitrogen Skp2 antibody (Invitrogen, 32-3300) was used in western blot on human samples (fig 8). Immunology (2010) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; fig 2
In order to explore how the COP9 signalosome affects ubiquitination processes, Invitrogen Skp2 antibody (Zymed, 32-3300) was used in western blot on human samples (fig 2). J Biol Chem (2010) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; fig 3
In order to study human papillomavirus type 18 E2 degradation, Invitrogen Skp2 antibody (Zymed, 32-3300) was used in western blot on human samples (fig 3). J Virol (2010) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; fig 3
In order to examine the role of Skp2 in the development of mechanical tension, Invitrogen Skp2 antibody (Zymed, 32-3300) was used in western blot on human samples (fig 3). Mol Cell Biol (2009) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; fig 3
In order to ascertain the effects of modulating Skp2 expression in melanoma cells, Invitrogen Skp2 antibody (Zymed, 8D9) was used in western blot on human samples (fig 3). Mol Biol Cell (2008) ncbi
mouse monoclonal (SKP2-8D9)
  • flow cytometry; human; fig 1
  • immunocytochemistry; human; fig 1
  • western blot; human; fig 1
In order to report that the Skp2-cyclin A interaction has a major role in cancer cell survival, Invitrogen Skp2 antibody (Zymed, 32-3,300) was used in flow cytometry on human samples (fig 1), in immunocytochemistry on human samples (fig 1) and in western blot on human samples (fig 1). Mol Cancer Ther (2007) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human
In order to examine how the COP9 signalosome regulates the cell cycle in human cells, Invitrogen Skp2 antibody (Zymed, 32-3300) was used in western blot on human samples . J Biol Chem (2006) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; fig 5
In order to study the role of B-RAF and cyclin D1 on p27Kip1 in human melanoma cells, Invitrogen Skp2 antibody (Zymed, Skp2-8D9) was used in western blot on human samples (fig 5). Oncogene (2007) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; fig 2
In order to determine the consequences of the Skp2-cyclin A interaction, Invitrogen Skp2 antibody (Zymed, 32-3300) was used in western blot on human samples (fig 2). J Biol Chem (2006) ncbi
mouse monoclonal (SKP2-8D9)
  • immunohistochemistry - paraffin section; human; 1:100; tbl 1
In order to study the category subdivision of pT1a and pT1b in renal cell carcinoma, Invitrogen Skp2 antibody (Zymed, SKP2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (tbl 1). BJU Int (2005) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human
In order to analyze the synergistic induction of apoptosis in T98G glioblastoma cells due to downregulation of Skp2 and p27/Kip1, Invitrogen Skp2 antibody (Zymed, 8D9) was used in western blot on human samples . J Mol Med (Berl) (2005) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human
In order to report that RhoA conveys the "cell shape signal" to the cell-cycle machinery in human capillary endothelial cells, Invitrogen Skp2 antibody (Zymed, SKP2-8D9) was used in western blot on human samples . J Biol Chem (2004) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; fig 2
In order to study phosphorylation of human Cdt1 and induction of its degradation due to cyclin-dependent kinases, Invitrogen Skp2 antibody (Zymed, 8D9) was used in western blot on human samples (fig 2). J Biol Chem (2004) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human
In order to study the mechanisms of Cdt1 degradation in mammalian cells, Invitrogen Skp2 antibody (Zymed, 8D9) was used in western blot on human samples . J Biol Chem (2003) ncbi
mouse monoclonal (SKP2-8D9)
  • western blot; human; 1:250
In order to assess the role of the SKP2 F-box protein in p27 regulation in prostate cancer, Invitrogen Skp2 antibody (Zymed, 32?C3300) was used in western blot on human samples at 1:250. BMC Cell Biol (2002) ncbi
Santa Cruz Biotechnology
mouse monoclonal (A-2)
  • western blot; human; loading ...; fig 2e
Santa Cruz Biotechnology Skp2 antibody (SantaCruz, sc-74477) was used in western blot on human samples (fig 2e). Oncotarget (2017) ncbi
Abcam
domestic rabbit monoclonal (EPR3305(2))
  • western blot; human; fig 2
Abcam Skp2 antibody (Abcam, ab183039) was used in western blot on human samples (fig 2). Oncotarget (2016) ncbi
Cell Signaling Technology
domestic rabbit polyclonal
  • immunoprecipitation; human; loading ...; fig 2f
  • western blot; human; loading ...; fig 5a
Cell Signaling Technology Skp2 antibody (Cell Signaling, 4358) was used in immunoprecipitation on human samples (fig 2f) and in western blot on human samples (fig 5a). Pharmaceutics (2022) ncbi
domestic rabbit monoclonal (D3G5)
  • western blot; human; 1:1000; fig 5h
Cell Signaling Technology Skp2 antibody (CST, 2652) was used in western blot on human samples at 1:1000 (fig 5h). Nat Commun (2021) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 5d
Cell Signaling Technology Skp2 antibody (Cell Signaling Technology, 4358) was used in western blot on human samples (fig 5d). Nat Commun (2020) ncbi
domestic rabbit polyclonal
  • western blot; mouse; loading ...; fig 3b
Cell Signaling Technology Skp2 antibody (Cell Signaling Technology, 4313) was used in western blot on mouse samples (fig 3b). Aging (Albany NY) (2020) ncbi
domestic rabbit monoclonal (D3G5)
  • immunocytochemistry; human; 1:1000; loading ...; fig s4f
  • western blot; human; 1:1000; loading ...; fig s4d
Cell Signaling Technology Skp2 antibody (Cell Signaling, 2652) was used in immunocytochemistry on human samples at 1:1000 (fig s4f) and in western blot on human samples at 1:1000 (fig s4d). Nat Commun (2018) ncbi
domestic rabbit polyclonal
  • western blot; human; 1:1000; loading ...; fig 5b
Cell Signaling Technology Skp2 antibody (New England Biolab, 4358) was used in western blot on human samples at 1:1000 (fig 5b). Oncogene (2018) ncbi
domestic rabbit monoclonal (D3G5)
  • western blot knockout validation; human; 1:1000; loading ...; fig 3i
Cell Signaling Technology Skp2 antibody (Cell Signaling, 2652) was used in western blot knockout validation on human samples at 1:1000 (fig 3i). Nat Commun (2018) ncbi
domestic rabbit monoclonal (D3G5)
  • immunohistochemistry; mouse; loading ...; fig 7h
  • immunoprecipitation; human; loading ...; fig 3a
  • immunohistochemistry; human; 1:1000; loading ...; fig 6b
  • western blot; human; 1:1000; loading ...; fig 1b
Cell Signaling Technology Skp2 antibody (cell signalling, 2652) was used in immunohistochemistry on mouse samples (fig 7h), in immunoprecipitation on human samples (fig 3a), in immunohistochemistry on human samples at 1:1000 (fig 6b) and in western blot on human samples at 1:1000 (fig 1b). Nat Commun (2017) ncbi
domestic rabbit monoclonal (D3G5)
  • western blot; human; 1:1000; loading ...; fig 2c
In order to identify and characterize an inhibitor of the COP9 signalosome, Cell Signaling Technology Skp2 antibody (Cell Signaling, 2652) was used in western blot on human samples at 1:1000 (fig 2c). Nat Commun (2016) ncbi
domestic rabbit monoclonal (D3G5)
  • western blot; human; loading ...; fig 2a
Cell Signaling Technology Skp2 antibody (Cell Signalling, 2652) was used in western blot on human samples (fig 2a). Oncotarget (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; fig 6
Cell Signaling Technology Skp2 antibody (Cell Signaling Tech, 4358) was used in western blot on human samples (fig 6). Cancer Sci (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; fig 2
Cell Signaling Technology Skp2 antibody (Cell Signaling, 4313) was used in western blot on human samples (fig 2). Oncotarget (2016) ncbi
domestic rabbit monoclonal (D3G5)
  • western blot; human; fig 3b
In order to study MARCKS signaling and how it expresses endothelial cell proliferation and vascular smooth muscle through a KIS-, p27kip1- dependent mechanism, Cell Signaling Technology Skp2 antibody (Cell Signaling Technology, 2652) was used in western blot on human samples (fig 3b). PLoS ONE (2015) ncbi
domestic rabbit monoclonal (D3G5)
  • western blot; human; 1:1000
Cell Signaling Technology Skp2 antibody (Cell Signaling Technology, 2652) was used in western blot on human samples at 1:1000. FEBS J (2014) ncbi
Articles Reviewed
  1. Deshmukh D, Xu J, Yang X, Shimelis H, Fang S, Qiu Y. Regulation of p27 (Kip1) by Ubiquitin E3 Ligase RNF6. Pharmaceutics. 2022;14: pubmed publisher
  2. Tang X, Li G, Shi L, Su F, Qian M, Liu Z, et al. Combined intermittent fasting and ERK inhibition enhance the anti-tumor effects of chemotherapy via the GSK3β-SIRT7 axis. Nat Commun. 2021;12:5058 pubmed publisher
  3. Li Z, Zhang H, Huang Y, Huang J, Sun P, Zhou N, et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat Commun. 2020;11:3806 pubmed publisher
  4. Cui J, Duan J, Chu J, Guo C, Xi M, Li Y, et al. Chikusetsu saponin IVa protects pancreatic β cell against intermittent high glucose-induced injury by activating Wnt/β-catenin/TCF7L2 pathway. Aging (Albany NY). 2020;12:1591-1609 pubmed publisher
  5. von Gamm M, Schaub A, Jones A, Wolf C, Behrens G, Lichti J, et al. Immune homeostasis and regulation of the interferon pathway require myeloid-derived Regnase-3. J Exp Med. 2019;: pubmed publisher
  6. Mentrup T, Theodorou K, Cabrera Cabrera F, Helbig A, Happ K, Gijbels M, et al. Atherogenic LOX-1 signaling is controlled by SPPL2-mediated intramembrane proteolysis. J Exp Med. 2019;: pubmed publisher
  7. Li Y, Liu Y, Xu H, Jiang G, Van der Jeught K, Fang Y, et al. Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II. Nat Commun. 2018;9:4394 pubmed publisher
  8. Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E, et al. Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. Oncogene. 2018;37:5701-5718 pubmed publisher
  9. Yao F, Zhou Z, Kim J, Hang Q, Xiao Z, Ton B, et al. SKP2- and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity. Nat Commun. 2018;9:2269 pubmed publisher
  10. Xu J, Zhou W, Yang F, Chen G, Li H, Zhao Y, et al. The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor. Nat Commun. 2017;8:14002 pubmed publisher
  11. Nagashima K, Fukushima H, Shimizu K, Yamada A, Hidaka M, Hasumi H, et al. Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression. Oncotarget. 2017;8:9947-9960 pubmed publisher
  12. Schlierf A, Altmann E, Quancard J, Jefferson A, Assenberg R, Renatus M, et al. Targeted inhibition of the COP9 signalosome for treatment of cancer. Nat Commun. 2016;7:13166 pubmed publisher
  13. Wang C, Guo S, Wang J, Yan X, Farrelly M, Zhang Y, et al. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922. Oncotarget. 2016;7:49597-49610 pubmed publisher
  14. Itsumi M, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, et al. Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2. Cancer Sci. 2016;107:1022-8 pubmed publisher
  15. Dai Y, Wang L, Tang J, Cao P, Luo Z, Sun J, et al. Activation of anaphase-promoting complex by p53 induces a state of dormancy in cancer cells against chemotherapeutic stress. Oncotarget. 2016;7:25478-92 pubmed publisher
  16. Pavlides S, Lecanda J, Daubriac J, Pandya U, Gama P, Blank S, et al. TGF-β activates APC through Cdh1 binding for Cks1 and Skp2 proteasomal destruction stabilizing p27kip1 for normal endometrial growth. Cell Cycle. 2016;15:931-47 pubmed publisher
  17. Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, et al. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget. 2016;7:4062-76 pubmed publisher
  18. Yu D, Makkar G, Dong T, Strickland D, Sarkar R, Monahan T. MARCKS Signaling Differentially Regulates Vascular Smooth Muscle and Endothelial Cell Proliferation through a KIS-, p27kip1- Dependent Mechanism. PLoS ONE. 2015;10:e0141397 pubmed publisher
  19. Evans L, Chen L, Milazzo G, Gherardi S, Perini G, Willmore E, et al. SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma. Cancer Lett. 2015;363:37-45 pubmed publisher
  20. Xu D, Li C, Zhang X, Gong Z, Chan C, Lee S, et al. Skp2-macroH2A1-CDK8 axis orchestrates G2/M transition and tumorigenesis. Nat Commun. 2015;6:6641 pubmed publisher
  21. Chen J, Shin J, Zhao R, Phan L, Wang H, Xue Y, et al. CSN6 drives carcinogenesis by positively regulating Myc stability. Nat Commun. 2014;5:5384 pubmed publisher
  22. Lupino E, Ramondetti C, Buccinnà B, Piccinini M. Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition. Biochem Pharmacol. 2014;92:235-50 pubmed publisher
  23. Ram R, Mendiratta S, Bodemann B, Torres M, Eskiocak U, White M. RASSF1A inactivation unleashes a tumor suppressor/oncogene cascade with context-dependent consequences on cell cycle progression. Mol Cell Biol. 2014;34:2350-8 pubmed publisher
  24. Kim J, Kim H, Park J, Park D, Cho Y, Sohn C, et al. Epidermal growth factor upregulates Skp2/Cks1 and p27(kip1) in human extrahepatic cholangiocarcinoma cells. World J Gastroenterol. 2014;20:755-73 pubmed publisher
  25. Tanaka T, Iino M. Knockdown of Sec8 promotes cell-cycle arrest at G1/S phase by inducing p21 via control of FOXO proteins. FEBS J. 2014;281:1068-84 pubmed publisher
  26. Segura M, Fontanals Cirera B, Gaziel Sovran A, Guijarro M, Hanniford D, Zhang G, et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 2013;73:6264-76 pubmed publisher
  27. Roe J, Kim H, Hwang I, Cho E, Youn H. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage. Oncogene. 2011;30:3127-38 pubmed publisher
  28. Rico Bautista E, Yang C, Lu L, Roth G, Wolf D. Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol. 2010;8:153 pubmed publisher
  29. Lupino E, Buccinnà B, Ramondetti C, Lomartire A, De Marco G, Ricotti E, et al. In CD28-costimulated human naïve CD4+ T cells, I-?B kinase controls the expression of cell cycle regulatory proteins via interleukin-2-independent mechanisms. Immunology. 2010;131:231-41 pubmed publisher
  30. Fernandez Sanchez M, Sechet E, Margottin Goguet F, Rogge L, Bianchi E. The human COP9 signalosome protects ubiquitin-conjugating enzyme 3 (UBC3/Cdc34) from beta-transducin repeat-containing protein (betaTrCP)-mediated degradation. J Biol Chem. 2010;285:17390-7 pubmed publisher
  31. Bellanger S, Tan C, Nei W, He P, Thierry F. The human papillomavirus type 18 E2 protein is a cell cycle-dependent target of the SCFSkp2 ubiquitin ligase. J Virol. 2010;84:437-44 pubmed publisher
  32. Jiang X, Austin P, Niederhoff R, Manson S, Riehm J, Cook B, et al. Mechanoregulation of proliferation. Mol Cell Biol. 2009;29:5104-14 pubmed publisher
  33. Hu R, Aplin A. Skp2 regulates G2/M progression in a p53-dependent manner. Mol Biol Cell. 2008;19:4602-10 pubmed publisher
  34. Ji P, Sun D, Wang H, Bauzon F, Zhu L. Disrupting Skp2-cyclin A interaction with a blocking peptide induces selective cancer cell killing. Mol Cancer Ther. 2007;6:684-91 pubmed
  35. Denti S, Fernandez Sanchez M, Rogge L, Bianchi E. The COP9 signalosome regulates Skp2 levels and proliferation of human cells. J Biol Chem. 2006;281:32188-96 pubmed
  36. Bhatt K, Hu R, Spofford L, Aplin A. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene. 2007;26:1056-66 pubmed
  37. Ji P, Goldin L, Ren H, Sun D, Guardavaccaro D, Pagano M, et al. Skp2 contains a novel cyclin A binding domain that directly protects cyclin A from inhibition by p27Kip1. J Biol Chem. 2006;281:24058-69 pubmed
  38. Langner C, Ratschek M, Rehak P, Tsybrovskyy O, Zigeuner R. The pT1a and pT1b category subdivision in renal cell carcinoma: is it reflected by differences in tumour biology?. BJU Int. 2005;95:310-4 pubmed
  39. Lee S, McCormick F. Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J Mol Med (Berl). 2005;83:296-307 pubmed
  40. Mammoto A, Huang S, Moore K, Oh P, Ingber D. Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27kip1 pathway and the G1/S transition. J Biol Chem. 2004;279:26323-30 pubmed
  41. Liu E, Li X, Yan F, Zhao Q, Wu X. Cyclin-dependent kinases phosphorylate human Cdt1 and induce its degradation. J Biol Chem. 2004;279:17283-8 pubmed
  42. Li X, Zhao Q, Liao R, Sun P, Wu X. The SCF(Skp2) ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. J Biol Chem. 2003;278:30854-8 pubmed
  43. Lu L, Schulz H, Wolf D. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol. 2002;3:22 pubmed